Bharat Biotech International Limited (BBIL) announced that iNCOVACC (BBV154), has received approval from the Drugs Controller General of India (DCGI) under Restricted Use in Emergency Situations for ages 18 and above, in India, for heterologous booster doses.
iNCOVACC is the world’s first Intranasal vaccine for COVID to receive approval for the primary 2-dose schedule and the heterologous booster dose. iNCOVACC is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized SARS-CoV-2 spike protein. This vaccine candidate was evaluated in phases I, II, and III clinical trials with successful results.
World AIDS Vaccine Day, also known as HIV Vaccine Awareness Day, is observed annually on…
The Indian government has announced plans for public sector companies like Coal India, NMDC, and…
In April, India's merchandise exports saw a modest 1% increase, reaching $34.99 billion, driven by…
The Open Network for Digital Commerce (ONDC), a digital infrastructure initiative launched in 2021, has…
In response to rising credit demand and falling liquidity, State Bank of India (SBI) has…
The Indian Army is poised to elevate its air defense capabilities with the impending delivery…